Pfizer plans higher prices post-pandemic To view this email as a web page,
click here Pfizer, Moderna and J&J tout supercharged COVID-19 vaccine output, eyeing nearly 140 million new doses by March Consumers' growing comfort with retail health could prove critical to vaccine effort: J.D. Power Pfizer eyes higher prices for COVID-19 vaccine after the pandemic wanes: exec, analyst Clover raises $230M as COVID-19 vaccine nears phase 3, multivariant prospect gets going FDA delivers new guidance for test makers on dealing with COVID-19's emerging strains UPDATED Coronavirus tracker: CVS to administer COVID vaccines at 81 Florida pharmacies OCR lifts HIPAA fines for use of COVID-19 vaccine scheduling tools Nasal spray prevents COVID-19 transmission in preclinical tests Featured Story | By Fraiser Kansteiner Pfizer, Moderna and Johnson & Johnson execs say they're working all the angles on increasing COVID-19 vaccine production and expect to amp up weekly deliveries by tens of millions by the end of March. Moderna plans to double its output by April, while Pfizer aims to roll out 13 million doses a week next month. read more |
| |
|---|
|
Top Stories By Paige Minemyer A growing number of Americans are turning to retail pharmacies for health and wellness services, which could make their role in the COVID-19 vaccine distribution even more crucial, according to a new study. read more By Eric Sagonowsky Amid the high-stakes fight against COVID-19, a company at the forefront of the vaccine effort is laying plans to hike prices after the crisis. A top Pfizer exec said the drugmaker aims to charge more after the "pandemic pricing environment," and an influential analyst says the company could be eying prices 3 to 4 times higher. read more By Nick Paul Taylor Clover Biopharmaceuticals has raised $230 million to take a COVID-19 vaccine candidate into a phase 2/3 clinical trial. The series C positions the Chinese biotech to validate the efficacy of its vaccine and gear up to manufacture hundreds of millions of doses this year. read more By Conor Hale As the U.S. passes a grim milestone with at least 500,000 deaths caused by COVID-19, the FDA is preparing to manage an ongoing and future threat from the disease: new viral mutations that may hinder the effectiveness of tests, treatments and vaccines. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Heather Landi Healthcare organizations won't be penalized for potential HIPAA violations related to the good faith use of online or web-based scheduling applications for vaccine COVID-19 appointments. The Office for Civil Rights announced this week that it won't enforce fines against providers when using apps and other digital tools that don't fully comply with HIPAA. read more By Nick Paul Taylor A nasally delivered SARS-CoV-2 fusion inhibitor has stopped the spread of the coronavirus in animals. The preclinical findings offer encouragement ahead of the generation of data on the effect of the spray on humans. read more |
|
